Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alphamab OncologyALMOF 12 EV-to-EBIT is -56.77 as of Aug. 27, 2026. GuruFocus rates ALMOF with a GF Score™ of 12/100 and a GF Value™ of $0.87 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 380 Biotechnology companies, Alphamab Oncology ranks worse than 263157.63% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Alphamab Oncology's Enterprise Value for the quarter that ended in Dec. 2025 was $0.00 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Alphamab Oncology's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $-15.19 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alphamab Oncology EV-to-EBIT Related Terms
Alphamab Oncology EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Alphamab Oncology's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Alphamab Oncology's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alphamab Oncology EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alphamab Oncology's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Alphamab Oncology's EV-to-EBIT falls into.
Alphamab Oncology's current Enterprise Value is $862.21 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Alphamab Oncology's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $-15.19 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alphamab Oncology (ALMOF) has a EV-to-EBIT of -56.77 as of Aug. 27, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Alphamab Oncology and its competitors. According to the industry distribution chart, Alphamab Oncology ranks #999999 out of 380 companies in the Biotechnology industry.
Is Alphamab Oncology's EV-to-EBIT too high?
Alphamab Oncology's current EV-to-EBIT is -56.77. Based on the distribution chart, Alphamab Oncology ranks #999999 out of 380 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Alphamab Oncology has a GF Score™ of 12/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Alphamab Oncology's EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Alphamab Oncology ranks #999999 out of 380 companies for EV-to-EBIT. This places Alphamab Oncology in the lower half of its industry. The industry median EV-to-EBIT is 15.92. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 15.92, based on 380 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Alphamab Oncology and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 15.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alphamab Oncology's current EV-to-EBIT is -56.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alphamab Oncology stock overvalued right now?
Based on GuruFocus' analysis, Alphamab Oncology (ALMOF) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.87, compared to a current price of $1.02 — trading 17.4% above its estimated fair value. The current EV-to-EBIT is -56.77. Alphamab Oncology's overall GF Score™ is 12/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Alphamab Oncology (ALMOF), the current EV-to-EBIT is -56.77 as of Aug. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alphamab Oncology (ALMOF) Overvalued in 2026?
Based on GuruFocus' analysis, Alphamab Oncology stock appears to be overvalued.
The current stock price of $1.02 is trading 17.4% above its estimated GF Value™ of $0.87.
GuruFocus considers Alphamab Oncology to be Modestly Overvalued.
Key valuation signals for ALMOF:
EV-to-EBIT: -56.77
GF Value™: $0.87 vs. price of $1.02 (17.4% above fair value)
No single metric tells the full story. See the ALMOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alphamab Oncology is a biopharmaceutical company in China with a fully integrated proprietary technology platform in ADCs, bispecific antibodies, and multifunctional protein engineering. The Company is principally engaged in the research and development, manufacturing, and commercialisation of biologics of oncology. It delivers therapeutic biologics by applying its drug discovery and development capabilities. Its product portfolio includes Envafolimab (KN035), KN026, JSKN003, JSKN016, JSKN033, JSKN022, JSKN027, JSKN021, KN019, and KN046.
12GF Score
Get the complete analysis for ALMOF
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ALMOF has been successfully added to your 
